Clinical Summary: Temporal Dynamics of Antidepressant Response Following Brexanolone Treatment in Postpartum Depression
Postpartum depression can impair maternal functioning, affect infant well-being, and is a leading cause of maternal death in the first year postpartum. For clinicians considering rapid-acting neuroactive steroid treatment, this study offers a close look at how quickly symptoms, anxiety, anhedonia, rumination, and maternal functioning changed during and after brexanolone treatment.
Key Findings
- All subjects showed clinical response following brexanolone (≥50% decrease from baseline total HAMD) by H72; 60% of subjects achieved response by H24, 80% achieved remission by H48, and by H72, 9 of 10 subjects had remitted.
- Across the 9 subjects who remitted, the mean time to remission was 39.1 hours (±16.2) from the beginning of the infusion, and at D30, remission was sustained for all 9 subjects who achieved remission during treatment.
- Anxiety improved substantially by H72 on both state and trait measures: STAI-S showed mean difference=−26.9, P<.001 and STAI-T showed mean difference=−27.3, P<.001, with slight further improvement at D30 (STAI-S, mean difference=−28.8, P<.001; STAI-T, mean difference=−33.1, P<.001).
- Residual symptom domains also improved rapidly: SHAPS score decreased by 89% from 6.2 (±3.7) to 0.7 (±1.1), mean difference= −5.5, P < .001, while RRS decreased by 29% from 28.4 (±2.5) to 20.3 (±8.3), mean difference= −8.1, P = .008.
- Self-reported maternal functioning improved markedly, with BIMF increasing 56% from baseline to H72 (58.5 [±9.2] to 91.3 [±16.8], mean difference = 32.8, P < .001) and further increases at D30 (mean difference = 42.7, P < .001).
Brexanolone treatment in this small inpatient PPD cohort was followed by rapid HAMD response and remission, with parallel gains in anxiety, anhedonia, rumination, and maternal functioning that were evident by H72 and sustained to D30 in those who remitted. Symptom trajectories were heterogeneous, so clinicians should expect fast improvement in some patients without assuming a single leading symptom or that scale-defined remission fully captures the patient’s subjective recovery.
Practice Implications
- Monitor patients closely in the first 24–48 hours of treatment, as 60% achieved response by H24 and 80% achieved remission by H48.
- Assess more than depressive severity alone during rapid recovery; anxiety, anhedonia, rumination, and maternal functioning all changed during the same treatment window.
- Ask directly about the patient’s experience of mood change and desired affective state, because subjective mood measures diverged from HAMD and STAI-S timing in 8 out of 10 participants.
- Interpret the observed temporal patterns cautiously in practice because the study was open-label, single-arm, and inpatient, included 10 participants, and all participants continued their prescribed antidepressants.
